Roisín M. Connolly

Also affiliated with Cork University Hospital

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 17 papers. Top paper: “Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers”.

Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2021-002473

N/A

2.5DataRank · unranked

67 citations

Karisa C. Schreck, Wei Fu, Chen Hu, Alexander Carvajal-González, Roisín M. Connolly +18 more

Entinostat Decreases Immune Suppression to Promote Antitumor Responses in a HER2+ Breast Tumor Microenvironment

Cancer Immunology Research(2022)10.1158/2326-6066.cir-21-0170

N/A

0.624DataRank · unranked

63 citations

Christine I. Rafie, Julie K. Jang, Sofi Castanon, Aaron G. Baugh, Edgar Gonzalez +21 more

A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013

npj Breast Cancer(2022)10.1038/s41523-022-00500-3

N/A

0.604DataRank · unranked

55 citations

Feng Gao, Cherease R. Street, Ina Chen, Donald W. Northfelt, Robert Wesolowski +21 more

Entinostat, nivolumab and ipilimumab for women with advanced HER2-negative breast cancer: a phase Ib trial

Nature Cancer(2024)10.1038/s43018-024-00729-w

N/A

0.587DataRank · unranked

49 citations

Won Jin Ho, Ludmila Danilova, Joseph A. Tandurella, James M. Leatherman, Christine I. Rafie +22 more

Phase I Study of Entinostat and Nivolumab with or without Ipilimumab in Advanced Solid Tumors (ETCTN-9844)

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-5017

N/A

0.538DataRank · unranked

35 citations

Christine I. Rafie, Chenguang Wang, David Lim, Adam Brufsky, Patricia LoRusso +16 more

Phase I Study and Cell-Free DNA Analysis of T-DM1 and Metronomic Temozolomide for Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-0855

N/A

0.477DataRank · unranked

23 citations

Wei Zhang, Seth M. Steinberg, Darryl Nousome, Nicole Houston, Xiaolin Wu +22 more

Phase I and Pharmacokinetic Study of Romidepsin in Patients with Cancer and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-1412

N/A

0.463DataRank · unranked

8 citations

Eric Laille, Ulka N. Vaishampayan, Vincent Chung, Karen Kelly, Afshin Dowlati +16 more

Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2 -Amplified Tumors: Results from the NCI–MATCH ECOG–ACRIN Trial (EAY131) Subprotocol J

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-23-0633

N/A

0.414DataRank · unranked

9 citations

Victoria Wang, Jaime B. Hyman, Petros Grivas, Edith P. Mitchell, John Wright +17 more

Trial in progress: A phase II open-label, randomized study of PARP inhibition (olaparib) either alone or in combination with anti-PD-L1 therapy (atezolizumab) in homologous DNA repair (HDR) deficient, locally advanced or metastatic non-HER2-positive breast cancer.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.tps1102

N/A

0.360DataRank · unranked

10 citations

Mary Josephine Paula Pilat, Cesar Augusto Santa-Maria, Roisín M. Connolly, Erin Roesch, Anosheh Afghahi +15 more

Association of treatment-emergent symptoms identified by patient-reported outcomes with adjuvant endocrine therapy discontinuation

npj Breast Cancer(2022)10.1038/s41523-022-00414-0

N/A

0DataRank · unranked

28 citations

Neha Verma, Amanda L. Blackford, Jennifer Lehman, Kelly Westbrook, David K. Lim +15 more

Automated lesion detection of breast cancer in [18F] FDG PET/CT using a novel AI-Based workflow

Frontiers in Oncology(2022)10.3389/fonc.2022.1007874

N/A

0DataRank · unranked

13 citations

Steven P. Rowe, Vered Stearns, Roisín M. Connolly, Christos Vaklavas, Minetta C. Liu +5 more

Exploring homologous recombination deficiency thresholds for predicting response to platinum-based treatment in triple negative breast cancer.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.525

N/A

0DataRank · unranked

0 citations

Lauren Lenz, Elizabeth S. Cogan, Erica L. Mayer, Virginia Kaklamani, Vered Stearns +15 more

HDAC inhibitors induce LIFR expression and promote a dormancy phenotype in breast cancer

Oncogene(2021)10.1038/s41388-021-01931-1

N/A

0DataRank · unranked

40 citations

Lauren Holtslander, Courtney Edwards, Vera M. Todd, Samuel Dooyema, Kennady K. Bullock +5 more

Impact of Muscle Measures on Outcome in Patients Receiving Endocrine Therapy for Metastatic Breast Cancer: Analysis of ECOG-ACRIN E2112

Journal of the National Comprehensive Cancer Network(2023)10.6004/jnccn.2023.7045

N/A

0DataRank · unranked

10 citations

Helga S. Marques, Gloria Xue, Richard L. Hoffman, Constantine Gatsonis, Fengmin Zhao +4 more

Data from A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART, SWOG S1609)

(2023)10.1158/1078-0432.c.6530837

N/A

0DataRank · unranked

0 citations

Megan Othus, Sandip Pravin Patel, Kathy D. Miller, Rashmi Chugh, Scott M. Schuetze +23 more

Olaparib Use in Patients With Metastatic Breast Cancer Harboring Somatic BRCA1/2 Mutations or Mutations in Non-BRCA1/2, DNA Damage Repair Genes

Clinical Breast Cancer(2021)10.1016/j.clbc.2021.12.007

N/A

0DataRank · unranked

15 citations

Neha Mangini, John H. Fetting, Deborah K. Armstrong, Isaac S. Chan, Roisín M. Connolly +13 more

Conducting a Virtual Clinical Trial in HER2-Negative Breast Cancer Using a Quantitative Systems Pharmacology Model With an Epigenetic Modulator and Immune Checkpoint Inhibitors

Frontiers in Bioengineering and Biotechnology(2020)10.3389/fbioe.2020.00141

N/A

0DataRank · unranked

52 citations

Richard J. Sové, Mohammad Jafarnejad, Sondra Rahmeh, Elizabeth M. Jaffee, Vered Stearns +4 more